Clinical Trials
18 trialsNCT07617753 2026-06-01
DUAL-OV-CAR-NK
Beijing Biotech
Phase 1/2 Recruiting
NCT05200559 2026-05-29
T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors
University of Pittsburgh
Phase 1/2 Active not recruiting
NCT07589543 2026-05-15
EB-DUALNK-OV
Beijing Biotech
Phase 1/2 Recruiting
NCT04902872 2026-05-12
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Cybrexa Therapeutics
Phase 1/2 Completed
NCT04152499 2026-05-11
MK-2870-001
Klus Pharma Inc.
Phase 1/2 Active not recruiting
NCT03393884 2026-05-04
OVATION 2
Imunon
Phase 1/2 Active not recruiting
NCT06395519 2026-03-27
ERADIC8
858 Therapeutics, Inc.
Phase 1/2 Recruiting
NCT07432633 2026-03-27
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
Blue Earth Diagnostics
Phase 1/2 Recruiting
NCT06412510 2026-03-18
Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT
Case Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT07480954 2026-03-18
DUAL-OV-CAR-NK
Beijing Biotech
Phase 1/2 Recruiting
NCT05325866 2026-02-04
FORTITUDE-301
Amgen
Phase 1/2 Completed
NCT05867251 2025-11-19
Study of AVZO-021 in Patients With Advanced Solid Tumors
Avenzo Therapeutics, Inc.
Phase 1/2 Recruiting
NCT05773859 2025-11-18
NEODOC
Radboud University Medical Center
Phase 1/2 Recruiting
NCT03519178 2025-11-14
A Study of PF-06873600 in People With Cancer
Pfizer
Phase 1/2 Terminated
NCT02611024 2025-07-09
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
PharmaMar
Phase 1/2 Completed
NCT05086692 2025-07-09
ABILITY-1
Medicenna Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06602063 2025-06-27
Surgery for Relapsed Ovarian Cancer in Precision
Shanghai Gynecologic Oncology Group
Phase 1/2 Not yet recruiting
NCT06087289 2025-06-08
KANDOVA
Novakand Pharma AB
Phase 1/2 Completed